Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Fenyö EM[au]:

Search results

Items: 1 to 50 of 237

1.

Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study.

Esbjörnsson J, Månsson F, Kvist A, da Silva ZJ, Andersson S, Fenyö EM, Isberg PE, Biague AJ, Lindman J, Palm AA, Rowland-Jones SL, Jansson M, Medstrand P, Norrgren H; Sweden and Guinea-Bissau Cohort Research Group.

Lancet HIV. 2018 Nov 1. pii: S2352-3018(18)30254-6. doi: 10.1016/S2352-3018(18)30254-6. [Epub ahead of print]

PMID:
30392769
2.

Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition.

Sheik-Khalil E, Bray MA, Özkaya Şahin G, Scarlatti G, Jansson M, Carpenter AE, Fenyö EM.

BMC Infect Dis. 2014 Aug 30;14:472. doi: 10.1186/1471-2334-14-472.

3.

Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals.

Esbjörnsson J, Månsson F, Kvist A, Isberg PE, Biague AJ, da Silva ZJ, Jansson M, Fenyö EM, Norrgren H, Medstrand P.

AIDS. 2014 Apr 24;28(7):949-57.

PMID:
24812673
4.

Effect of HIV-2 infection on HIV-1 disease progression and mortality.

Esbjörnsson J, Månsson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, da Silva ZJ, Jansson M, Fenyö EM, Norrgren H, Medstrand P.

AIDS. 2014 Feb 20;28(4):614-5. doi: 10.1097/QAD.0000000000000142. No abstract available.

PMID:
24469002
5.

High intrapatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch.

Mild M, Gray RR, Kvist A, Lemey P, Goodenow MM, Fenyö EM, Albert J, Salemi M, Esbjörnsson J, Medstrand P.

Infect Genet Evol. 2013 Oct;19:369-77. doi: 10.1016/j.meegid.2013.05.004. Epub 2013 May 11.

PMID:
23672855
6.

Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.

Özkaya Şahin G, Månsson F, Palm AA, Vincic E, da Silva Z, Medstrand P, Norrgren H, Fenyö EM, Jansson M.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):470-8. doi: 10.1089/AID.2012.0219. Epub 2012 Nov 21.

7.

Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Özkaya Şahin G, Holmgren B, Sheik-Khalil E, da Silva Z, Nielsen J, Nowroozalizadeh S, Månsson F, Norrgren H, Aaby P, Fenyö EM, Jansson M.

J Virol. 2013 Jan;87(1):273-81. doi: 10.1128/JVI.01640-12. Epub 2012 Oct 17.

8.

Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection.

Esbjörnsson J, Månsson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, da Silva ZJ, Jansson M, Fenyö EM, Norrgren H, Medstrand P.

N Engl J Med. 2012 Jul 19;367(3):224-32. doi: 10.1056/NEJMoa1113244.

9.

International network for comparison of HIV neutralization assays: the NeutNet report II.

Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyö EM, Scarlatti G.

PLoS One. 2012;7(5):e36438. doi: 10.1371/journal.pone.0036438. Epub 2012 May 9.

10.

Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Ozkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjörnsson J, Månsson F, Andersson S, Norrgren H, Aaby P, Jansson M, Fenyö EM.

J Virol. 2012 Jan;86(2):961-71. doi: 10.1128/JVI.06315-11. Epub 2011 Nov 9.

11.

Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.

Fenyö EM, Esbjörnsson J, Medstrand P, Jansson M.

J Intern Med. 2011 Dec;270(6):520-31. doi: 10.1111/j.1365-2796.2011.02455.x. Epub 2011 Oct 27.

12.

Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries.

Vinner L, Holmgren B, Jensen KJ, Esbjornsson J, Borggren M, Hentze JL, Karlsson I, Andresen BS, Gram GJ, Kloverpris H, Aaby P, Da Silva ZJ, Fenyö EM, Fomsgaard A.

APMIS. 2011 Aug;119(8):487-97. doi: 10.1111/j.1600-0463.2011.02763.x. Epub 2011 May 14.

PMID:
21749448
13.

Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.

Borggren M, Repits J, Sterjovski J, Uchtenhagen H, Churchill MJ, Karlsson A, Albert J, Achour A, Gorry PR, Fenyö EM, Jansson M.

PLoS One. 2011;6(6):e20135. doi: 10.1371/journal.pone.0020135. Epub 2011 Jun 16.

14.

Inhibition of splicing by serine-arginine rich protein 55 (SRp55) causes the appearance of partially spliced HIV-1 mRNAs in the cytoplasm.

Tranell A, Tingsborg S, Fenyö EM, Schwartz S.

Virus Res. 2011 Apr;157(1):82-91. doi: 10.1016/j.virusres.2011.02.010. Epub 2011 Feb 21.

PMID:
21345357
15.

High prevalence of HIV-1, HIV-2 and other sexually transmitted infections among women attending two sexual health clinics in Bissau, Guinea-Bissau, West Africa.

Månsson F, Camara C, Biai A, Monteiro M, da Silva ZJ, Dias F, Alves A, Andersson S, Fenyö EM, Norrgren H, Unemo M.

Int J STD AIDS. 2010 Sep;21(9):631-5. doi: 10.1258/ijsa.2010.009584.

PMID:
21097735
16.

Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.

Ozkaya Sahin G, Bowles EJ, Parker J, Uchtenhagen H, Sheik-Khalil E, Taylor S, Pybus OG, Mäkitalo B, Walther-Jallow L, Spångberg M, Thorstensson R, Achour A, Fenyö EM, Stewart-Jones GB, Spetz AL.

PLoS Pathog. 2010 Sep 2;6(9):e1001084. doi: 10.1371/journal.ppat.1001084.

17.

Serine- and arginine-rich proteins 55 and 75 (SRp55 and SRp75) induce production of HIV-1 vpr mRNA by inhibiting the 5'-splice site of exon 3.

Tranell A, Fenyö EM, Schwartz S.

J Biol Chem. 2010 Oct 8;285(41):31537-47. doi: 10.1074/jbc.M109.077453. Epub 2010 Aug 4.

18.

Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children.

Cavarelli M, Karlsson I, Ripamonti C, Plebani A, Fenyo EM, Scarlatti G.

AIDS. 2010 Oct 23;24(16):2527-33. doi: 10.1097/QAD.0b013e32833d7d8c.

PMID:
20683317
19.

High sexual risk taking and diverging trends of HIV-1 and HIV-2 in the military of Guinea Bissau.

Biague A, Månsson F, da Silva Z, Dias F, Nantote Q, Costa J, Andersson S, Nauclér A, Biberfeld G, Fenyö EM, Norrgren H.

J Infect Dev Ctries. 2010 Jun 3;4(5):301-8.

20.

Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West Africa.

Esbjörnsson J, Månsson F, Martínez-Arias W, Vincic E, Biague AJ, da Silva ZJ, Fenyö EM, Norrgren H, Medstrand P.

Retrovirology. 2010 Mar 22;7:23. doi: 10.1186/1742-4690-7-23.

21.

Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections.

Nowroozalizadeh S, Månsson F, da Silva Z, Repits J, Dabo B, Pereira C, Biague A, Albert J, Nielsen J, Aaby P, Fenyö EM, Norrgren H, Holmgren B, Jansson M.

J Infect Dis. 2010 Apr 15;201(8):1150-4. doi: 10.1086/651430.

PMID:
20199244
22.

Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection.

Wade J, Sterjovski J, Gray L, Roche M, Chiavaroli L, Ellett A, Jakobsen MR, Cowley D, Pereira Cda F, Saksena N, Wang B, Purcell DF, Karlsson I, Fenyö EM, Churchill M, Gorry PR.

Virology. 2010 Jan 20;396(2):246-55. doi: 10.1016/j.virol.2009.10.029. Epub 2009 Nov 13.

23.

Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.

Hinkula J, Walther-Jallow L, Laurén A, Mäkitalo B, Oberg M, Wahren B, Fenyö EM, Spetz AL.

Vaccine. 2009 Oct 30;27(46):6424-31. doi: 10.1016/j.vaccine.2009.06.016. Epub 2009 Jun 21.

PMID:
19549607
24.

Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa.

Månsson F, Biague A, da Silva ZJ, Dias F, Nilsson LA, Andersson S, Fenyö EM, Norrgren H.

AIDS. 2009 Jul 31;23(12):1575-82. doi: 10.1097/QAD.0b013e32832cedfb.

PMID:
19521234
25.

Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.

Mild M, Kvist A, Esbjörnsson J, Karlsson I, Fenyö EM, Medstrand P.

Infect Genet Evol. 2010 Apr;10(3):356-64. doi: 10.1016/j.meegid.2009.05.003. Epub 2009 May 14.

PMID:
19446658
26.

Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections.

Nowroozalizadeh S, Månsson F, da Silva Z, Repits J, Dabo B, Pereira C, Biague A, Albert J, Nielsen J, Aaby P, Fenyö EM, Norrgren H, Holmgren B, Jansson M.

Cytokine. 2009 Jun;46(3):325-31. doi: 10.1016/j.cyto.2009.03.003. Epub 2009 Apr 17.

PMID:
19375940
27.

International network for comparison of HIV neutralization assays: the NeutNet report.

Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G.

PLoS One. 2009;4(2):e4505. doi: 10.1371/journal.pone.0004505. Epub 2009 Feb 20.

28.

HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children.

Cavarelli M, Karlsson I, Zanchetta M, Antonsson L, Plebani A, Giaquinto C, Fenyö EM, De Rossi A, Scarlatti G.

PLoS One. 2008 Sep 29;3(9):e3292. doi: 10.1371/journal.pone.0003292.

29.

Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.

Repits J, Sterjovski J, Badia-Martinez D, Mild M, Gray L, Churchill MJ, Purcell DF, Karlsson A, Albert J, Fenyö EM, Achour A, Gorry PR, Jansson M.

Virology. 2008 Sep 15;379(1):125-34. doi: 10.1016/j.virol.2008.06.014. Epub 2008 Jul 30.

30.

Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin.

Nowroozalizadeh S, Jansson M, Adamsson J, Lindblad M, Fenyö EM, Holmgren J, Harandi AM.

Curr HIV Res. 2008 May;6(3):230-8.

PMID:
18473786
31.

Sensitivity of HIV type 1 primary isolates to human anti-CD40 antibody-mediated suppression is related to coreceptor use.

Abayneh SA, Ellmark P, Karlsson U, Andersson H, Borrebaeck CA, Karlsson I, Fenyö EM.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):447-52. doi: 10.1089/aid.2007.0216.

PMID:
18373433
32.

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.

Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyö EM, Montefiori DC, McCutchan FE, Michael NL.

Virology. 2008 Jun 5;375(2):315-20. doi: 10.1016/j.virol.2008.02.007. Epub 2008 Mar 25. Review.

33.

Identification of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infection.

Ellmark P, Andersson H, Abayneh S, Fenyö EM, Borrebaeck CA.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):367-73. doi: 10.1089/aid.2007.0215.

PMID:
18327984
34.

Biological and genetic evolution of HIV type 1 in two siblings with different patterns of disease progression.

Ripamonti C, Leitner T, Laurén A, Karlsson I, Pastore A, Cavarelli M, Antonsson L, Plebani A, Fenyö EM, Scarlatti G.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1531-40.

PMID:
18160011
35.

Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.

Sterjovski J, Churchill MJ, Ellett A, Gray LR, Roche MJ, Dunfee RL, Purcell DF, Saksena N, Wang B, Sonza S, Wesselingh SL, Karlsson I, Fenyo EM, Gabuzda D, Cunningham AL, Gorry PR.

Retrovirology. 2007 Dec 12;4:89.

36.

CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates.

Laurén A, Vincic E, Hoshino H, Thorstensson R, Fenyö EM.

Retrovirology. 2007 Jul 23;4:50.

37.

Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998 1999.

Månsson F, Alves A, Silva ZJ, Dias F, Andersson S, Biberfeld G, Fenyö EM, Norrgren H.

Sex Transm Infect. 2007 Oct;83(6):463-7. Epub 2007 Jul 4.

38.

Introduction: HIV neutralizing antibodies: relevance to pathogenesis and vaccines.

Albert J, Chiodi F, Fenyö EM.

J Intern Med. 2007 Jul;262(1):2-4. Review. No abstract available.

39.

Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch.

Mild M, Esbjörnsson J, Fenyö EM, Medstrand P.

J Virol. 2007 Apr;81(7):3369-76. Epub 2007 Jan 24.

41.

Isolation of human immunodeficiency virus-type 1 (HIV-1) clones with biological and molecular properties of the primary isolate.

Mild M, Björndal A, Medstrand P, Fenyö EM.

Virology. 2006 Jun 20;350(1):58-66. Epub 2006 Mar 24.

43.
44.

Coreceptor usage of primary HIV type 1 isolates obtained from different lymph node subsets.

Casper C, Mild M, Jansson M, Karlsson A, Holmberg V, Bratt G, Van Paaschen H, Biberfeld P, Björndal A, Albert J, Popovic M, Fenyö EM.

AIDS Res Hum Retroviruses. 2005 Dec;21(12):1003-10.

PMID:
16379603
45.

Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.

Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, Moberg L, Broström C, Fenyö EM, Albert J.

J Gen Virol. 2005 Dec;86(Pt 12):3385-96.

PMID:
16298986
46.

Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.

Repits J, Oberg M, Esbjörnsson J, Medstrand P, Karlsson A, Albert J, Fenyö EM, Jansson M.

J Gen Virol. 2005 Oct;86(Pt 10):2859-69.

PMID:
16186242
47.

Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue.

Karlsson I, Grivel JC, Chen SS, Karlsson A, Albert J, Fenyö EM, Margolis LB.

J Virol. 2005 Sep;79(17):11151-60.

48.

Quantitative evaluation of HIV and SIV co-receptor use with GHOST(3) cell assay.

Vödrös D, Fenyö EM.

Methods Mol Biol. 2005;304:333-42.

PMID:
16061987
49.

Plaque-reduction assays for human and simian immunodeficiency virus neutralization.

Nordqvist A, Fenyö EM.

Methods Mol Biol. 2005;304:273-85.

PMID:
16061983
50.

The X4 phenotype of HIV type 1 evolves from R5 in two children of mothers, carrying X4, and is not linked to transmission.

Clevestig P, Maljkovic I, Casper C, Carlenor E, Lindgren S, Navér L, Bohlin AB, Fenyö EM, Leitner T, Ehrnst A.

AIDS Res Hum Retroviruses. 2005 May;21(5):371-8.

PMID:
15929699

Supplemental Content

Loading ...
Support Center